Skip to main content
Premium Trial:

Request an Annual Quote

Bio-Rad's Credit Rating Raised by S&P

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Standard & Poor's today raised its corporate credit rating on Bio-Rad Laboratories to "BBB" from "BBB-" with a stable outlook.

The credit rating service also said that it had raised Bio-Rad's senior subordinated rating to "BBB-" from "BB+".

"The upgrade reflects Bio-Rad's continued solid operating performance and cash flow generation, despite recent challenges in the life science industry," S&P Credit Analyst Arthur Wong said in a statement.

S&P said that it expects Bio-Rad to continue to generate solid growth and free cash flows and to benefit from increasing economic stimulus-related life sciences funding.

In Friday afternoon trade on the New York Stock Exchange, shares of Bio-Rad were up 1 percent at $112.51.

The Scan

Not Yet a Permanent One

NPR says the lack of a permanent Food and Drug Administration commissioner has "flummoxed" public health officials.

Unfair Targeting

Technology Review writes that a new report says the US has been unfairly targeting Chinese and Chinese-American individuals in economic espionage cases.

Limited Rapid Testing

The New York Times wonders why rapid tests for COVID-19 are not widely available in the US.

Genome Research Papers on IPAFinder, Structural Variant Expression Effects, Single-Cell RNA-Seq Markers

In Genome Research this week: IPAFinder method to detect intronic polyadenylation, influence of structural variants on gene expression, and more.